Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Kezar Life Sciences, Inc. (KZR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.74-0.03 (-0.34%)
At close: 4:00PM EDT
8.74 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close8.77
Open8.90
Bid8.59 x 1000
Ask9.79 x 1100
Day's Range8.60 - 8.90
52 Week Range4.61 - 9.79
Volume81,429
Avg. Volume258,324
Market Cap421.205M
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)-0.95
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KZR

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kezar Life Sciences, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Insider Monkey

    10 Pharmaceutical Stocks to Buy According to Lawrence Hawkins’ Prosight Capital

    In this article, we discuss 10 pharmaceutical stocks to buy according to Lawrence Hawkins’ Prosight Capital. If you want to skip our detailed analysis of Hawkins’ history, investment philosophy, and hedge fund performance, go directly to the 5 Pharmaceutical Stocks to Buy According to Lawrence Hawkins’ Prosight Capital. Lawrence Hawkins, the managing partner of Dallas-based […]

  • Business Wire

    Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs

    SOUTH SAN FRANCISCO, Calif., October 05, 2021--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Gitanjali Jain as Vice President, Investor Relations and External Affairs. As a member of the management team and executive committee, Ms. Jain will lead Kezar’s overall investor relations, public relations, and scientific communications effo

  • TipRanks

    3 Hot Growth Stocks to Beat the Market Volatility

    Volatility is back on the menu. U.S. stocks began the week deeply in the red as investors grappled with a number of risks, including a possible shift in Federal Reserve guidance this week that could hurt corporate profits. There are also concerns that Evergrande - a major Chinese property developer - could default on its hundreds of billions in debt and trigger a financial crisis beyond China. The key to success in this environment is really the same as in ‘normal’ times. Look for stocks with so

Advertisement
Advertisement